drugset / Trial / NCT01523821
Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Phase 1/2
Completed
20 enrolled
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I/II trial evaluates the efficacy and adverse effects of alpha 1 anti-trypsin (AAT) for the treatment of acute graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation.
Timeline
- Start
- 2013-10-11
- Primary completion
- 2017-01-15
- Completion
- 2017-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | 30 mg/kg | Intravenous |
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | 60 mg/kg | Intravenous |
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | 90 mg/kg | Intravenous |